Zacks Research Issues Negative Estimate for Neogen Earnings

Neogen Co. (NASDAQ:NEOG) – Zacks Research lowered their Q3 2025 EPS estimates for Neogen in a report issued on Tuesday, January 28th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.12 for the quarter, down from their prior estimate of $0.14. The consensus estimate for Neogen’s current full-year earnings is $0.41 per share. Zacks Research also issued estimates for Neogen’s Q4 2025 earnings at $0.13 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.52 EPS.

Other equities analysts also recently issued research reports about the stock. Guggenheim initiated coverage on shares of Neogen in a research note on Thursday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. Piper Sandler reaffirmed a “neutral” rating and issued a $13.00 target price (down previously from $16.50) on shares of Neogen in a report on Tuesday, January 21st.

Neogen Stock Performance

Shares of NASDAQ NEOG opened at $11.50 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. Neogen has a 12 month low of $10.72 and a 12 month high of $18.58. The stock has a 50-day moving average price of $12.58 and a two-hundred day moving average price of $14.73.

Neogen (NASDAQ:NEOG) last posted its quarterly earnings results on Friday, January 10th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.12. The business had revenue of $231.30 million during the quarter, compared to the consensus estimate of $227.16 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. Neogen’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.11 earnings per share.

Insider Buying and Selling

In other news, CEO John Edward Adent bought 23,035 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was acquired at an average price of $11.03 per share, with a total value of $254,076.05. Following the completion of the purchase, the chief executive officer now directly owns 269,164 shares in the company, valued at $2,968,878.92. This represents a 9.36 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO David H. Naemura purchased 14,800 shares of the stock in a transaction on Thursday, January 16th. The stock was acquired at an average cost of $11.11 per share, with a total value of $164,428.00. Following the completion of the purchase, the chief financial officer now directly owns 61,434 shares of the company’s stock, valued at $682,531.74. The trade was a 31.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Neogen

Several institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC grew its holdings in shares of Neogen by 142.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after acquiring an additional 1,165 shares during the period. Blue Trust Inc. grew its stake in Neogen by 196.7% in the fourth quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock worth $41,000 after purchasing an additional 2,233 shares during the period. Neo Ivy Capital Management bought a new position in Neogen in the third quarter worth $66,000. KBC Group NV lifted its position in Neogen by 39.1% during the fourth quarter. KBC Group NV now owns 8,464 shares of the company’s stock valued at $103,000 after buying an additional 2,379 shares during the period. Finally, Marco Investment Management LLC bought a new stake in shares of Neogen during the 3rd quarter valued at $169,000. Hedge funds and other institutional investors own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.